# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹257 Cr** Q2 FY26 (+34%) · **₹503 Cr** H1 FY26 (+36%) * **EBITDA:** **₹82 Cr** Q2 FY26 (+100%) · **₹152 Cr** H1 FY26 (+96%) · **8%** Q2 margin (+1,030 bps) · **30%** H1 margin (+930 bps) * **PAT:** **₹51 Cr** Q2 FY26 (+134%) · **₹92 Cr** H1 FY26 (+135%) · **20%** Q2 margin (+860 bps) · **18%** H1 margin (+780 bps) * **Cash PAT:** **₹116 Cr** H1 FY26 (+94%) * ROCE / ROE: 42.3% / 32.7% (as of 30th September 2025) * **Debt-to-Equity:** **3x** · **Fixed Asset Turnover:** **2x** (as of Sep 2025) ## B. Revenue Growth * **Robust Top-Line Acceleration:** Revenue growth remained strong across periods, led by the high-performing Healthcare segment and expanding product portfolio. ## C. Margin Expansion * **Sharp Margin Leverage:** EBITDA margins expanded dramatically year-on-year, driven by **IP-led pen platforms** and a shift toward higher-margin offerings. * **Sustained Margin Outlook:** Management expects current EBITDA margin levels to hold into FY27, with upside potential if Healthcare scales further and gains revenue mix share. ## D. Profitability Trends * **Disproportionate Bottom-Line Growth:** PAT surged well ahead of revenue, reflecting operating leverage and significant margin expansion. * **Cash Earnings Strength:** Cash PAT reached **₹116 Cr** in H1, underscoring improving earnings quality despite modest ROCE/ROE. * **Healthcare Profitability Target:** Segment may deliver **₹100 Cr revenue** and **₹50 Cr PAT** in coming quarters, signaling material contribution ahead. ## E. Cash Flow Strength * **Capital Structure Note:** High debt-to-equity ratio of **3x** reflects capital-intensive positioning, partially offset by solid fixed asset turnover of **2x**. --- # 2. Segment & Revenue Mix ## A. Key Figures * Healthcare Revenue Mix: 38% of total revenue (doubled from prior share) * **Exports:** **68%** of revenue (Q2 FY'26) · **72%** of revenue (H1 FY'26) * **Segmental Revenue (Q2 FY'26):** **Consumer ₹135 Cr** (–3%) · **Pharma ₹99 Cr** (+163%) · **Industrial ₹23 Cr** (+45%) * **Segmental Revenue (H1 FY'26):** **Consumer ₹286 Cr** (+6%) · **Pharma ₹176 Cr** (+171%) · **Industrial ₹41 Cr** (+17%) ## B. Healthcare Segment * **Strategic Expansion:** Healthcare now a core pillar, doubling its revenue contribution on the back of global engagement and new product launches. * **C. K. Subsidiary Performance:** Maintains **₹20 Cr/quarter run rate** over recent quarters, though forward visibility remains unconfirmed. * **Market Leadership:** Holds **dominant position** in Indian generics; expected to remain **largest supplier** in Brazil, Turkey, and India despite unspecified market share. ## C. Consumer Segment * **Pharma Drives Growth:** Segment portfolio shows divergent trends—Pharma surges with **strong triple-digit growth**, while Consumer grows modestly due to **large base effect**. * **New Project Wins:** Awarded **5 new projects** from major home furnishings clients, reinforcing customer stickiness and market presence. * **Consumer Electronics Breakthrough:** Commercial supply expected in H2; represents **$20–100 Mn** multi-year opportunity, underpinned by **unique domestic precision manufacturing capability**. ## D. Industrial Segment * **Project Pipeline:** Secured **1 new automotive project** during the quarter, signaling continued traction in industrial verticals. --- # 3. Product & Therapy Performance ## A. Key Figures * **User Priming Behavior:** **Over 96%** of users do not prime before first use, creating under-dosing risk mitigated by Axiom Max design * **Device Length:** **26 mm total extension**, approximately half the length of competitor devices (42–50 mm) ## B. GLP-1 Devices * **Next-Gen Launch:** Commercial rollout of **Axiom Max**, a fixed-dose GLP-1 pen with **no priming requirement**, **dose counter**, and **low injection force**, strengthens competitive positioning in global innovator partnerships. * **Differentiation & IP:** Device offers **three to four key advantages** over incumbents, including **unique dose counter mechanism** protected by pre-launch patents, enhancing IP moat. * **Targeted Market Penetration:** Adoption in existing programs contingent on **molecule scalability** and client **margin headroom**, as Axiom Max is not positioned as a cost-plus solution. * **Global Demand Dynamics:** All **23–24 GLP-1 partners** are developing both Ozempic and Wegovy; outside the U.S., **pen-based delivery dominates**, aligning with company’s core device expertise. ## C. Insulin & Auto-injectors * **Emerging Traction:** Spring-driven devices like **Neo** are gaining momentum with no anticipated adoption barriers, signaling early validation in adjacent delivery segments. * **Strategic Focus:** Insulin device growth expected long-term, but near-term market momentum and R&D prioritization remain centered on **GLP-1 franchise expansion**. --- # 4. Capacity & Manufacturing ## A. Key Figures * Pen Manufacturing Capacity: 40 Mn units current → 80 Mn units targeted by end-FY26 * Polymer Processing Volume: **6,652 tons** Q2 FY'26 (+7.5%) · **13,668 tons** H1 FY'26 (+13.1%) * **Machine Utilization Rate:** **48%** (Q2 & H1 FY'26) * **Capex for Pen Expansion:** **~INR 125 Cr** allocated in FY26 * **New Machines Installed:** **19** in Q2 FY26 ## B. Pen Manufacturing * **Aggressive Capacity Build:** Significant expansion underway to double output by end-FY26, with **19 new machines already installed** and new line now expected online by end-Q3 FY26. * **Strategic Flexibility:** Excess capacity provides optionality to shift across product lines and absorb volatility, supporting delivery of **8 crore total device target** despite timing delays. * **Commercial Readiness Confirmed:** **Commercial-scale production is live**, indicating customer or CDMO partners are already scaling assembly, validating product launch preparedness. * **Focus on High-Growth Devices:** Expansion prioritizes **GLP-1 pens**, with insulin pen output expected to scale to **2–5 crore units** by FY26 end. * **Toby Capacity Under Review:** **~1 crore unit expansion** considered but not finalized, with no current capex commitment. ## C. Machine Utilization * **Low Utilization, High Headroom:** Current **48% machine utilization** reflects ongoing ramp-up phase, with management signaling meaningful improvement ahead as new lines come online. ## D. Capex Plans * **No Middle East Manufacturing:** Firm stance against setting up factories in **Dubai or Abu Dhabi**, with no plans for large-scale capex in the region. * **Consumer Electronics: Light-Touch Expansion:** Growth in Bangalore and Mysore areas will leverage **existing infrastructure**, requiring only **marginal capex** for tooling and automation—no major investments planned. --- # 5. Customer & Project Wins ## A. Key Figures * **New Projects Signed:** **4** in healthcare (GLP-1 and other therapies) * **Customer Meetings:** **130+** held at global events during the quarter * **Direct GLP-1 Partners:** **23–24** with extended network amplifying reach * **Axiom Max Engagements:** **18** dedicated meetings across 3 exhibitions ## B. New Healthcare Projects * **Strategic Project Mix:** Half of the new healthcare projects are for **emergency-use molecules**, highlighting regulatory agility and rapid deployment capability. * **Global Demand Tailwinds:** Expanding opportunity in post-patent markets across geographies, with strong interest from **Indian firms advancing from Ozempic to Wegovy development**. * **Service Expansion:** Shaily Innovations FZCO broadening scope beyond engineering to include **filing, testing, and cartridge filling**, targeting APAC, South Asia, and Middle East. * **Commercial Momentum:** **Commercial batches now live for Canada**, validating scale-up execution and market access. ## C. Consumer Electronics Wins * **Customer Depth Over Breadth:** Recent wins with **existing clients**, including long-term and newly onboarded customers, reflect strong relationship leverage and cross-selling success. ## D. Global Partner Network * **Enhanced Market Penetration:** Presence in **key global hubs** (Frankfurt, Vienna, Boston) driving a **>50% increase in annual customer meetings** year-on-year. * **Strategic Geographic Focus:** Initial commercial focus on **Europe and the Middle East**, with Dubai subsidiary evolving into a regional innovation node. * **High Partner Density:** Collaboration with **50–60% of Canada’s registered players** underscores dominant positioning in a concentrated market. --- # 6. Regulatory & Launch Risks ## A. Key Figures * **Commercial Batch Delay:** **5-month delay** in manufacturing, though other activities remain on track ## B. Filing Timelines * **Regulatory Risk Dominant:** Launch timelines hinge primarily on approvals, with **Wegovy filings lagging Ozempic** in Canada and Brazil due to later submissions. * **Market Dynamics:** Canadian market currently **dominated by Ozempic**, while uncertainty remains around generic erosion of innovator share. ## C. Customer Delays * **Supply Chain Resilience:** Company has **de-risked exposure** to customer-specific delays by serving multiple clients per platform and maintaining supply flexibility, even under a 12-month launch delay. * **Contractual Safeguards:** **Take-or-pay clauses** and committed volumes mitigate concentration risk; support for customers during setbacks is bounded by agreed terms. * **Limited Cross-Market Impact:** Delays in Canada’s generic launch **do not affect regulatory pathways** or timelines in other regions. * **Near-Term Timeline Stability:** Management sees **no major launch delays**, with potential shifts of up to **2 months** considered immaterial to overall commercial plans. ## D. Approval Dependencies * **Generic Launch Confidence:** Despite individual customer regulatory issues (e.g., Dr. Reddy’s), Shaily has onboarded **majority of GLP-1 generic players**, supporting expected market entry. * **Oral GLP-1 Limitations:** Oral alternatives face **severely constrained potential** due to **<10% bioavailability** vs. injectables and high API demands, limiting clinical and commercial viability. * **Strategic Industry Shift:** Global diabetes firms are prioritizing **GLP-1 over insulin programs**, pushing meaningful insulin device scale-up to **FY '27 or FY '28**. --- # 7. Guidance & Outlook ## A. Key Figures * **Healthcare Segment Growth:** **30–40%** annually projected * **Oral Market Penetration:** Up to **25–30%** of total market expected ## B. Revenue Trajectory * **Limited Near-Term Contribution:** New Consumer Electronics revenues to begin in H2 FY26 but will remain **non-significant** in FY26 and FY27, with meaningful impact expected only from FY28. * **Execution Timeline:** Commercial supply start after **6–8 months** of project execution; innovator breakthroughs possible in **1–5 years**, though supply lags by **3–4 years** post-device selection. ## C. Growth Projections * **Sustained Margin Expansion:** Gross margin trend expected to improve, though subject to **quarterly product mix** fluctuations. * **Healthcare Momentum:** Segment positioned for **strong double-digit growth** on robust demand and advanced pipeline execution. ## D. Market Expansion * **Resilient Semaglutide Positioning:** Despite Canadian regulatory uncertainty, Shaily’s **budget and supply remain unchanged**, with most filers having selected its device. * **Long-Term Diversification Potential:** Consumer Electronics and Semicon segments represent a **significant opportunity** given global market size and India’s manufacturing growth, though scale relative to IKEA business remains uncertain.